Siltuximab (CNTO328, Centocor, Inc., Horsham, PA, USA), an anti-IL-6 antibody, is in phase I/II clinical trials in patients with advanced solid tumors, including CRC [68]. This evidence concerns the gene IL6 and colorectal carcinoma.